Posts tagged latanoprost
BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.

Read More
HCW downgrades Inotek to neutral

H.C. Wainwright downgraded Inotek Pharmaceuticals (NASDAQ:ITEK) to “neutral” from “buy” and slashed its price target to $2 from $7 after a failed Phase 2 trial. The stock closed at 96 cents on July 11.

Read More
Stifel ups Aerie Pharma price target to $50

Stifel raised it price target for Aerie Pharmaceuticals (NASDAQ:AERI) to $50 from $40 after the company’s Roclatan eye drop hit all its endpoints with clinically meaningful results in a Phase 3 trial. The stock closed at $21.13 on Wednesday.

Analyst Annabel Samimy writes that the 90-day primary efficacy readout of the MERCURY-1 trial demonstrated statistically significant lowering of intraocular pressure (IOP) of Roclatan over its Rhopressa and latanoprost components.

Read More